AAAnthony Aizer

Anthony Aizer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anthony Aizer has a total of 223 co-authors. Here are the top co-authors by number of shared publications:

  • Douglas Holmes

    Leon H. Charney Division of Cardiology, NYU Langone Health New York University Grossman School of Medicine New York New York USA

    30 shared publications
  • Larry A. Chinitz

    Leon H. Charney Division of Cardiology, NYU Langone Health, New York, USA

    30 shared publications
  • Chirag R. Barbhaiya

    Leon H. Charney Division of Cardiology New York University Langone Health New York New York USA

    24 shared publications
  • Scott Bernstein

    Leon H. Charney Division of Cardiology, NYU Langone Health New York University Grossman School of Medicine New York New York USA

    22 shared publications
  • Lior Jankelson

    Leon H. Charney Division of Cardiology, NYU Langone Health New York University Grossman School of Medicine New York New York USA

    18 shared publications
  • David Park

    Leon H. Charney Division of Cardiology New York University Langone Health New York City New York USA

    16 shared publications

Latest Publications

  • Leadless Pacemaker Implant Location as a Predictor of Pacing Induced Cardiomyopathy

    by Alexander Kushnir, Mones Aboelatta, Robert Donnino, Douglas Holmes, Chirag R. Barbhaiya, Scott Bernstein, Lior Jankelson, Anthony Aizer, Leonid Garber, Larry A. Chinitz

    Background: Leadless pacemakers (LPs) avoid the lead‐ and pocket‐related complications of transvenous systems, but they pace exclusively from the right ventricle (RV), and chronic RV pacing carries a recognized risk of pacing‐induced cardiomyopathy (PICM). Whether implant location within the RV, a potentially modifiable factor, contributes to this risk has not been established. Methods: Patients undergoing LP implantation with ≥50% RV pacing, pre‐and post‐procedural echocardiograms, and post‐implant 3‐dimensional radiographic imaging were included. All implants targeted the RV septum per manufacturer recommendation. PICM was defined as ≥10% decline in left ventricular ejection fraction (LVEF) to P P <0.001) and discriminated free wall from non‐free wall implantation with an area under the receiver operating characteristic curve (AUC) of 0.85; a QRS duration of 172 ms provided optimal discrimination. Baseline LVEF, baseline QRS duration, and comorbidity burden did not differ between groups. Conclusions: Inadvertent free wall LP implantation is strongly associated with the subsequent development of PICM. Paced QRS duration is a readily available surrogate for implant location, and targeting a paced QRS duration below approximately 172 ms at the time of implant may serve as a practical, non‐invasive check on appropriate septal placement.

  • Pulmonary Vein Isolation (PVI) Versus PVI With Posterior Wall Isolation With PFA for Paroxysmal Atrial Fibrillation

    by Joey Junarta, Angela Wang, Eli Reynolds, Aristides Hatzimemos, Pooja Patel, Danielle Shields, Felix Yang, Chirag R. Barbhaiya, Lior Jankelson, Douglas Holmes, et al.

    Background: The value of additional lesion sets beyond pulmonary vein isolation (PVI) for atrial fibrillation (AF) ablation is unclear. However, existing studies evaluated the utility of substrate modification with conventional energy sources. There is limited data evaluating PVI with posterior wall isolation (PWI) using pulsed field ablation (PFA). Methods: We studied consecutive cases of patients with paroxysmal AF undergoing first‐time ablation with PFA between May 6, 2024 and March 10, 2025. Procedural data collected included the number of PFA applications administered, total procedure time, and major periprocedural complications. Clinical data collected included atrial tachyarrhythmia (ATA) recurrence, stroke, and major bleeding at 1‐year follow‐up. Outcomes were compared in patients undergoing PVI alone versus PVI plus PWI. Results: A total of 249 patients were included in this study (104 PVI alone, 145 PVI plus PWI). There was no difference in ATA recurrence by Kaplan–Meier survival analysis comparing PVI alone versus PVI plus PWI (log rank test p = 0.89). When comparing PVI alone versus PVI plus PWI, there was no difference in ATA recurrence at 1 year (16% vs. 16%; p = 0.92), AF burden on continuous monitoring (2% vs. 2%; p = 0.81), total procedure time (114 vs. 107 min; p = 0.14), or major periprocedural complications (0 vs. 3; p = 0.14). Conclusion: PFA for paroxysmal AF with PVI alone or PVI plus PWI produces similar sinus rhythm maintenance without affecting procedure times or complication rates.

  • The Utility of Higher Pulsed Field Ablation Applications for Atrial Fibrillation Ablation

    by Joey Junarta, Eli Reynolds, Angela Wang, Aristides Hatzimemos, Pooja Patel, Danielle Shields, Felix Yang, Chirag R. Barbhaiya, Lior Jankelson, Douglas Holmes, et al.

    Background: The optimal number of pulsed field ablation (PFA) applications during atrial fibrillation (AF) ablation is unclear. We hypothesized that the number of PFA applications would predict atrial tachyarrhythmia (ATA) recurrence rates. Objective: To determine whether higher numbers of PFA applications would decrease ATA recurrence rates. Methods: We studied cases of patients with AF undergoing first‐time ablation with PFA between 5/6/24 and 10/7/24. All patients underwent pulmonary vein and posterior wall isolation. The primary outcome was ATA recurrence. Additional outcomes included stroke, post‐procedural acute kidney injury (AKI), total procedure time, and major periprocedural complications. Univariable and multivariable analyses were performed to determine if the number of PFA applications predicted ATA recurrence. Results: In a cohort consisting of 177 patients, univariable and multivariable analysis showed that the number of PFA applications split at the smallest quartile (< 57 applications) versus the largest three quartiles (≥ 57 applications) was the strongest predictor of ATA recurrence ( p = 0.03). ATA recurrence at 1 year (29% vs. 8%; p < 0.01) and AF burden on continuous monitor (4% vs. 0%; p < 0.01) was higher with the standard (< 57 applications) vs higher (≥ 57 applications) PFA dose groups. When comparing the standard versus higher PFA dose groups, there was no difference in total procedure time (106 vs. 107 min; p = 0.77), major periprocedural complications (0% vs. 2%; p = 0.33), or post‐procedural AKI (2% vs. 2%; p = 0.69). Conclusion: Increasing number of PFA applications is associated with reduced ATA recurrence. A higher number of PFA applications may decrease ATA recurrence without affecting procedure times or complication rate.

  • The utility of high-frequency jet ventilation in pulsed field ablation for atrial fibrillation

    by Joey Junarta, Eli Reynolds, Angela Wang, Pooja Patel, Aristides Hatzimemos, Danielle Shields, Patrick Linton, Felix Yang, Chirag R. Barbhaiya, Lior Jankelson, et al.

    Using high-frequency jet ventilation (HFJV) to improve catheter stability with conventional energy sources during atrial fibrillation (AF) ablation is associated with higher ablation success and improved arrhythmic outcomes. The utility of HFJV with pulsed field ablation (PFA) for AF is unclear. We investigated the utility of HFJV vs. standard ventilation in PFA for AF. We studied consecutive cases of patients with AF undergoing PFA between 5/6/24 to 10/10/24. Procedural data collected included total procedure time and major periprocedural complications. Clinical data collected included atrial tachyarrhythmia (ATA) recurrence, stroke, and major bleeding at one-year follow-up. Outcomes were compared in cases where HFJV was used vs. standard ventilation. A total of 512 patients were included in this study (307 standard ventilation, 205 HFJV). There was no difference in ATA recurrence by Kaplan-Meier survival analysis between standard ventilation and HFJV groups (log rank test p = 0.59). When comparing standard ventilation vs. HFJV groups, there was no difference in ATA recurrence at one year (23% vs. 26%; p = 0.43), AF burden on continuous monitoring (9 ± 5% vs. 8 ± 24%; p = 0.85), total procedure time (114 ± 38 vs. 115 ± 33 min; p = 0.78), or major periprocedural complications (3% vs. 2%; p = 0.64). There was no difference in arrhythmic outcomes when patients were stratified by AF type and whether patients presented for first-time or redo ablation. Using HFJV in PFA for AF produces similar sinus rhythm maintenance overall and when stratified by AF type without affecting procedure times or complication rate.

  • Vein of Marshall Ethanol Ablation as a Strategy for Recurrent Persistent Atrial Fibrillation

    by Brian C. Hsia, Peter Zhang, Joey Junarta, Leonid Garber, Felix Yang, Michael Spinelli, Yury Malyshev, Alexander Kushnir, Lior Jankelson, Scott Bernstein, et al.

    Background: Vein of Marshall (VOM) ethanol ablation is effective in preventing recurrence in patients with persistent atrial fibrillation (AF) as a de novo strategy. There is minimal data on its use in recurrent AF. Objective: We investigated the efficacy of VOM ethanol ablation for recurrence despite initial AF ablation. Methods: Retrospective analysis was performed of persistent AF patients who underwent repeat ablation after an initial ablation for persistent AF. All patients had pulmonary vein isolation (PVI), posterior wall isolation (PWI), and cavotricuspid isthmus (CTI) during their previous ablation(s). At redo ablation, controls underwent confirmation and completion of previous ablation steps, substrate modification, and a search for non‐PV triggers. Cases had additional VOM ethanol ablation combined with mitral isthmus ablation. Results: One hundred and seven patients (49 VOM, 60 control) were included. There was no difference in AF recurrence at 1‐year comparing VOM patients (47%) and controls (38%), ( p = 0.39). Within the VOM group, the mean AF burden decreased from 38% preablation to 10% 12‐months post ( p = 0.003). The proportion of recurrent persistent AF decreased from 65% preablation to 26% post ( p = 0.004). There was no significant difference in reduction in AF burden or proportion of recurrent persistent AF when comparing VOM cases and controls. Six percent of VOM patients developed intraprocedural left atrial appendage (LAA) isolation. Conclusions: In patients with previous PVI, PWI, and CTI ablation, VOM ethanol ablation did not demonstrate a reduction in AF recurrence or burden when compared with a strategy of substrate modification and trigger ablation alone and increases the risk of LAA isolation.


  • Peak frequency analysis distinguishes nearfield from farfield signals during pulmonary vein isolation

    by Peter G. Ting, Chirag R. Barbhaiya, Lior Jankelson, Douglas S. Holmes, Alexander Kushnir, Felix Yang, Scott A. Bernstein, David S. Park, Larry A. Chinitz, Anthony Aizer


  • Persistent Left Atrial Appendage Thrombus in Atrial Fibrillation Despite Anticoagulation

    by Alexander Kushnir, Scott Bernstein, Chirag R. Barbhaiya, Lior Jankelson, Douglas Holmes, Anthony Aizer, David Park, Michael Spinelli, Leonard Garber, Felix Yang, et al.

    Objectives: Assess the characteristics and management of patients with LAA thrombus despite compliance with oral anticoagulation (OAC).Background: Atrial fibrillation guidelines consider 4 weeks of uninterrupted OAC sufficient to avoid transesophageal echocardiography to rule out left atrial appendage thrombus. However, some patients may exhibit persistent thrombus despite compliance with OAC.Methods: Clinical history, management, and outcomes were reviewed for patients with LAA thrombus on preprocedural TEE presenting for an AF related procedure between 2021 and 2024.Results: Sixty‐five (1.8%) of 3653 preprocedural TEEs exhibited LAA thrombus. OAC compliance of at least 4 week was documented in 39 (60%) of these patients, including Apixaban 64%, Rivaroxaban 23%, Warfarin 8%, Dabigatran 5%. Two of these patients (3%) experienced an embolic event and 8 (12%) died during the follow up period. Resolution of LAA thrombus was documented in 12/32 patients, 6 who switched to Dabigatran, 2 to Eliquis, 1 to Warfarin, and 3 remained on Eliquis. LAA‐occlusion was successfully performed in seven patients with persistent LAA thrombus. CHADS‐VASc 3 or greater, HFrEF, or valvular AF were present in 37/39 of these patients.Conclusion: For 3653 patients who underwent Preprocedural TEE, 39 exhibited LAA thrombus despite compliance with OAC. Switching OAC or maintaining the same agent for longer period of time resolved the thrombus in 31% of cases. LAA‐O was effective in cases where the thrombus did not resolve. Patients with non‐valvular AF, compliance with OAC > 4 weeks, CHADS‐VASc ≤ 2, and normal EF exhibited the lowest probability for not having a thrombus on TEE.


  • Personalized ablation strategies optimize first-pass isolation and minimize pulmonary vein reconnection during paroxysmal atrial fibrillation ablation

    by Joey Junarta, Jessica Qiu, Austin V. Cheng, Chirag R. Barbhaiya, Lior Jankelson, Douglas Holmes, Alexander Kushnir, Robert J. Knotts, Felix Yang, Scott A. Bernstein, et al.

  • Open Access

    Performance of a Protein Language Model for Variant Annotation in Cardiac Disease

    by Aviram Hochstadt, Chirag Barbhaiya, Anthony Aizer, Scott Bernstein, Marina Cerrone, Leonid Garber, Douglas Holmes, Robert J. Knotts, Alex Kushnir, Jacob Martin, et al.

    Background: Genetic testing is a cornerstone in the assessment of many cardiac diseases. However, variants are frequently classified as variants of unknown significance, limiting the utility of testing. Recently, the DeepMind group (Google) developed AlphaMissense, a unique artificial intelligence–based model, based on language model principles, for the prediction of missense variant pathogenicity. We aimed to report on the performance of AlphaMissense, accessed by VarCardio, an open web‐based variant annotation engine, in a real‐world cardiovascular genetics center. Methods and Results: All genetic variants from an inherited arrhythmia program were examined using AlphaMissense via VarCard.io and compared with the ClinVar variant classification system, as well as another variant classification platform (Franklin by Genoox). The mutation reclassification rate and genotype–phenotype concordance were examined for all variants in the study. We included 266 patients with heritable cardiac diseases, harboring 339 missense variants. Of those, 230 (67.8%) were classified by ClinVar as either variants of unknown significance or nonclassified. Using VarCard.io, 198 variants of unknown significance (86.1%, 95% CI, 80.9–90.3) were reclassified to either likely pathogenic or likely benign. The reclassification rate was significantly higher for VarCard.io than for Franklin (86.1% versus 34.8%, P <0.001). Genotype–phenotype concordance was highly aligned using VarCard.io predictions, at 95.9% (95% CI, 92.8–97.9) concordance rate. For 109 variants classified as pathogenic, likely pathogenic, benign, or likely benign by ClinVar, concordance with VarCard.io was high (90.5%). Conclusions: AlphaMissense, accessed via VarCard.io, may be a highly efficient tool for cardiac genetic variant interpretation. The engine's notable performance in assessing variants that are classified as variants of unknown significance in ClinVar demonstrates its potential to enhance cardiac genetic testing.